¸ÎÔà×÷ΪÈËÌåÖØÒªÆ÷¹Ù£¬Í¨³£¾ßÓдúл¹¦ÄÜ¡¢½â¶¾¹¦ÄÜ¡¢·ÖÃÚµ¨Ö¡¢´¢´æ¹¦ÄÜÒÔ¼°ÄýѪºÍÃâÒß¹¦ÄÜ¡£ÕâЩ¹¦ÄÜÏ໥Ð×÷£¬¹²Í¬Î¬³Ö»úÌåÄÚ»·¾³Îȶ¨¡£È»¶ø½ü¼¸Äê¸Î°©³ÉΪÁËÍþвÈËÀཡ¿µµÄÖØ´óÒþ»¼¡£ºÜ¶àʱºò¸Î°©Ò»µ©È·Õï¾ÍÊÇØ¬ºÄ£¬¼´Îª¸Î°©ÍíÆÚ£¬´Ëʱ¶ÔÓÚ¼ÒÍ¥Óë¸öÈËÀ´Ëµ¶¼ÊdzÁÖØµÄ´ò»÷£¬ÄѵÀ¾ÍûÓÐÖÎÁÆ·½·¨ÁËÂ𣿸ΰ©ÍíÆÚÔõô°ì£¿Ò׸ÊÌ©®îÆ90΢Çò×¢ÉäÒºÈò»ÉÙÈË¿´µ½ÁËÐÂÏ£Íû¡£ Ô·¢ÐԸΰ©ÊÇÈ«ÇòÖØ´ó½¡¿µÌôÕ½£¬ÆäÖиÎϸ°û°©£¨HCC£©ÓÈΪͻ³ö£¬Æä·¢²¡ÂÊλ¾ÓÈ«Çò¶ñÐÔÖ×ÁöµÚÁù룬ÖÂËÀÂÊλÁа©Ö¢Ïà¹ØËÀÍöµÚÈýλ[1]¡£ÁÙ´²Êý¾ÝÏÔʾ£¬³õÕïʱ½öÉÙÊý»¼Õß·ûºÏ¸ùÖÎÐÔÖÎÁƱê×¼£¨ÈçÏûÈÚÊõ¡¢ÇгýÊõºÍ¸ÎÒÆÖ²Êõ£©¡£ÎÞ·¨½ÓÊܸùÖÎÖÎÁƵϼÕßĿǰÖ÷Òª²ÉÓÃÃâÒßÖÎÁÆ¡¢¾¶¯Âö»¯ÁÆË¨ÈûºÍîÆ-90£¨Y90£©Ñ¡ÔñÐÔÄÚ·ÅÉäÖÎÁƵȹÃÏ¢ÐÔÖÎÁÆÊÖ¶Î[2-4]¡£2022°æBCLCÖ¸Ä϶ÔÑ¡ÔñÐÔÄÚ·ÅÉäÖÎÁÆ£¨SIRT£©µÄÊÊÓ¦Ö¢½øÐÐÁËÑϸñÏÞ¶¨£º½öÍÆ¼öÓÃÓÚµ¥·¢Ö×ÁöÖ±¾¶<8cm¡¢Child-Pugh A¼¶¡¢ÃÀ¹ú¶«²¿Ö×ÁöÐ×÷×飨ECOG£©ÌåÄÜ״̬ÆÀ·Ö0/1·ÖµÄBCLC 0ÆÚºÍAÆÚ»¼Õß[5]¡£ÕâÒ»ÏÞÖÆÖ÷Òª»ùÓÚÏÖÓÐIIIÆÚÁÙ´²Ñо¿½á¹û——ÓëË÷À·ÇÄáµ¥Ò©»òÁªºÏ·½°¸Ïà±È£¬SIRTδÄÜÏÔʾ³öÏÔÖøÉú´æ»ñÒæ[6,7]¡£µ«ÖµµÃÉÌȶµÄÊÇ£¬ÕâЩÑо¿ÔÚÉè¼ÆÉÏ´æÔÚÃ÷ÏÔ¾ÖÏÞ£º¼Èδ¿¼ÂǸöÌ廯¼ÁÁ¿²â¶¨µÄÖØÒªÐÔ£¬Ò²È±·¦ÏµÍ³µÄ¼ÁÁ¿Ñ§²ÎÊý·ÖÎö[8]¡£ ½üÆÚ£¬Ò»ÏîÀ´×Ô°ÍÎ÷µÄµ¥ÖÐÐĻعËÐÔÑо¿·¢ÏÖ£ºîÆ-90£¨SIRT£©ÖÎÁƸΰ©Ê±£¬µ±Ö×ÁöÎüÊÕ¼ÁÁ¿£¾138.8Gy£¬»¼Õ߿͹ۻº½âÂÊÌáÉý85%£¨p=0.003£©¡£ÕâÒâζמ«×¼¼ÁÁ¿¿ØÖÆ¿ÉÄܽ«ÍíÆÚ¸Î°©µÄ¹ÃÏ¢ÖÎÁÆ×ª»¯Îª¸ùÖλú»á¡£
ÕýÎÄ Ñо¿ÄÉÈë2014Äê11ÔÂÖÁ2023Äê4ÔÂÆÚ¼ä½ÓÊÜÖÎÁƵÄ27Àý»¼Õߣ¨¹²58¸ö°Ð²¡Ô¡£Í¨¹ýÓ°ÏñÈí¼þ·ÖÎö»¼Õß¼ÁÁ¿·Ö²¼ÌØÕ÷£¬ÆÀ¹ÀÖÎÁƺóÁÙ´²¼°Ó°Ïñѧ·´Ó¦£¬²¢²ÉÓÃͳ¼ÆÑ§·½·¨ÑéÖ¤ÎüÊÕ¼ÁÁ¿ÓëÖ×Áö¿Í¹Û»º½âµÄÏà¹ØÐÔ¡£¼ÁÁ¿¼ÆËã·½·¨£ºÌå±íÃæ»ý·¨£¨BSA£©20Àý£¬·ÖÇø·¨5Àý£¬MIRD·¨2Àý¡£ °Ð²¡ÔîµÄ¸ü¸ßÎüÊÕ¼ÁÁ¿Óë¸ÄÉÆµÄ¿Í¹Û»º½âÂÊÏÔÖøÏà¹Ø
±í 1 ¿Í¹Û»º½âÓëÖ×ÁöÌå»ý·ÖÎö ¶Ô¿Í¹Û»º½â¡¢Ö×ÁöÌå»ýºÍÆäËûÎüÊÕ¼ÁÁ¿²ÎÊýµÄÊý¾Ý½øÐÐ×ܽᣨ±í1£©£¬·¢ÏÖÕý³£¸ÎÔàµÄƽ¾ùÌå»ýΪ1630.9ºÁÉý£¨± 536.5£©£¬Æ½¾ù¼ÁÁ¿Îª27.5Gy¡£ÔÚÑо¿µÄ58¸ö²¡±äÖУ¬42¸ö£¨72.4%£©ÏÔʾÁ˿͹ۻº½â¡£¸Ã×鲡±äµÄƽ¾ùÎüÊÕ¼ÁÁ¿Îª138.8Gy£¬¶øÎ´ÏÔʾ¿Í¹Û»º½âµÄ²¡±äÎüÊÕ¼ÁÁ¿Îª74.5Gy£¨p=0.003£©¡£ ÔÚËùÓÐÑо¿µÄ°Ð²¡±äÖУ¬´ïµ½¿Í¹Û»º½âÓëD30Ϊ165.9Gy£¨p=0.021£©¡¢D50Ϊ109.4Gy£¨p=0.001£©ºÍD70Ϊ68.8Gy£¨p=0.021£©³ÊÕýÏà¹Ø¡£ÔÚBCLC C·ÖÐ͵ϼÕßÖУ¬ÏÔʾ¿Í¹Û»º½âµÄ²¡±ä£¨19/31£©Æ½¾ùÌå»ýΪ311.3ºÁÉý£¨Î޿͹ۻº½âµÄΪ181.4ºÁÉý£¬p=0.5£©£¬Æ½¾ùÎüÊÕ¼ÁÁ¿Îª115.9Gy£¬¶øÎ´ÏÔʾ¿Í¹Û»º½âµÄ²¡±äΪ67.2Gy£¨p=0.024£©¡£ ÎüÊÕ²¡±ä¼ÁÁ¿±ê×¼²îµÄPearsonÏà¹ØÐÔ±íÃ÷£¬×î´óºÍƽ¾ùÎüÊÕ¼ÁÁ¿µÄÖµÔ½¸ß£¬D70¡¢D50ºÍD30Ö®¼äµÄ±äÒìÐÔÔ½´ó£¨·Ö±ðΪR=0.513ºÍR=0.957£¬p<0.001£©¡£
ͼ1£º»ùÓÚÆ½¾ù¼ÁÁ¿£¨×ó£©ÓëîÆ90ÉãÈ¡Á¿£¨ÓÒ£©Çø·Ö¿Í¹Û»º½âЧÄÜ Í¨¹ýROCÇúÏß¶ÔÆ½¾ùʹÓüÁÁ¿¡¢D30¡¢D50ºÍD70²ÎÊýµÄ¿Í¹Û»º½âЧÄܽøÐÐÆÀ¹À£¨Í¼1¡¢±í2£©¡£½á¹ûÏÔʾ£¬ËùÓмÁÁ¿Ñ§²ÎÊýµÄÇúÏßÏÂÃæ»ý£¨AUC£©¾ù´óÓÚ0.7£¬ÆäÖÐD30µÄAUC×î¸ß£¨0.734£©£¬ÁÙ½çֵΪ71Gy£¬Ãô¸ÐÐÔΪ76.2%£¬ÌØÒìÐÔΪ56.2%¡£Æ½¾ù¼ÁÁ¿µÄAUCΪ0.707£¬ÁÙ½çֵΪ89.5Gy£¬Ãô¸ÐÐÔΪ61.9%£¬ÌØÒìÐÔΪ68.7%¡£ÕâЩÊý¾Ý±íÃ÷£¬´ïµ½¸ü¸ß¼ÁÁ¿ãÐÖµÓë¸ü¼ÑÁÙ´²½á¾ÖÏà¹Ø£¬Ö¤Êµ¼ÁÁ¿-·´Ó¦¹ØÏµ¶ÔÓÅ»¯ÖÎÁÆ·½°¸¾ßÓйؼüÒâÒå¡£
±í2£º»ùÓÚÆ½¾ù¼ÁÁ¿ºÍY90ÉãÈ¡µÄ¿Í¹Û»º½âЧÄÜ·ÖÎö¡£ ÒÔÍù¶àÏîÑо¿·¢ÏÖ£¬îÆ90΢ÇòµÄÖÎÁƼÁÁ¿¾ßÓйؼüÓ°Ïì¡£2012ÄêµÄÒ»ÏîÑо¿·¢ÏÖ£¬½ÓÊÜ90Y SPECT/CT¼ÁÁ¿ÆÀ¹À²¢³¬¹ý91GyµÄ»¼Õߣ¬¶¼·ûºÏRECIST±ê×¼£¬ÏÔʾ³ö½ÏºÃµÄÖÎÁÆ·´Ó¦[9,10]¡£Ò»ÏîÑо¿Í¨¹ýAUC¼ÁÁ¿-Ìå»ýÖ±·½Í¼¶ÔÊ÷֬΢ÇòµÄ¼ÁÁ¿ãÐÖµ½øÐзÖÎö£¬È·¶¨ÁË61GyµÄãÐÖµÓÃÓÚÔ¤²âÖ×Áö¿ØÖÆ£¬¾ßÓнϸߵÄÌØÒìÐÔºÍÃô¸ÐÐÔ[11]¡£»ùÓÚSARAHÊÔÑéµÄÊý¾Ý·ÖÎö·¢ÏÖ£¬Ö×ÁöÎüÊÕ¼ÁÁ¿³¬¹ý100GyµÄ»¼Õß¼²²¡¿ØÖÆÂʽϸߣ¬ÇÒÉú´æÆÚÏÔÖøÑÓ³¤[12]¡£»¹ÓÐÑо¿Ìá³ö£¬SIRTÖÎÁÆÊ±£¬Ö×ÁöÎüÊÕ¼ÁÁ¿Ó¦±£³ÖÔÚ100µ½120GyÖ®¼ä£¬¶ø¸ÎÔàµÄ±ê×¼¼ÁÁ¿Ó¦µÍÓÚ40Gy[13]¡£ ½üÄêÀ´£¬¸öÐÔ»¯¼ÁÁ¿Ñ§Öð½¥³ÉΪ¸Î°©ÖÎÁƵÄÇ÷ÊÆ£¬ÌرðÊÇÔÚÊ÷֬΢ÇòÖÎÁÆÖС£Ñо¿ÏÔʾ£¬Ôö¼ÓÖ×ÁöÎüÊÕ¼ÁÁ¿ÄÜÏÔÖø¸ÄÉÆÖÎÁÆÐ§¹ûÇÒ²»Ôö¼Ó°²È«·çÏÕ[14]¡£Ò»Ïî¹ØÓÚY90ÖÎÁƵĹú¼Êר¼Ò½¨ÒéÎļþÌá³ö£¬¸öÐÔ»¯¼ÁÁ¿Ñ§Ä£ÐÍÊÇÖÎÁƳɹ¦µÄ¹Ø¼ü£¬½¨Òé·ÇÖ×ÁöÐÔÖʵĸÎÔàÇøÓòµÄƽ¾ùÎüÊÕ¼ÁÁ¿Ó¦≤40Gy£¬¶øÖ×ÁöµÄ×îСÖÎÁƼÁÁ¿Ó¦Îª100-120Gy [15]¡£Ñо¿ÏÔʾ£¬Ö×ÁöÖÎÁƵļÁÁ¿Ñ§ãÐÖµ²»½öÒÀÀµÓÚ¼ÁÁ¿±¾Éí£¬»¹ÓëÖÎÁƹý³ÌÖÐ΢ÇòµÄ·Ö²¼ºÍÖ×ÁöµÄÒìÖÊÐÔÃÜÇÐÏà¹Ø¡£ÔÚ½ÓÊÜ´óÓÚ120GyÖÎÁƵIJ¡±äÖУ¬mRECIST·´Ó¦ÓëÉú´æÆÚÖ®¼äµÄ¹ØÏµ¸üΪÏÔÖø£¬Ìáʾ¸ü¸ßµÄ¼ÁÁ¿¿ÉÄÜ´øÀ´¸ü³¤µÄÎÞ½øÕ¹Éú´æÆÚ[16]¡£Ö®ºóµÄÑо¿½øÒ»²½È·ÈÏ£¬Ê÷֬΢ÇòµÄ¼ÁÁ¿ãÐÖµÓëÖÎÁÆ·´Ó¦³ÊÏÖÏÔÖøµÄ¹ØÁª£¬¸ß¼ÁÁ¿ÖÎÁÆÄܹ»ÏÔÖøÌá¸ßÍêÈ«·´Ó¦ÂʺÍÃô¸ÐÐÔ[17]¡£µ«ÖµµÃ×¢ÒâµÄÊÇ£¬ËäÈ»ÕâЩ¼ÁÁ¿ãÐÖµÓÐÒ»¶¨µÄÆÕ±éÐÔ£¬µ«ÈÔÊÜÖ×Áö´óС¡¢»µËÀ³Ì¶ÈÒÔ¼°Ë¨Èû¼¼ÊõµÈÒòËØµÄÓ°Ï죬Òò´Ë£¬Ã¿¸ö²¡ÀýµÄ¼ÁÁ¿Ñ§²ÎÊýÐèÒª¸ù¾Ý¾ßÌåÇé¿ö½øÐиöÐÔ»¯µ÷Õû¡£ ×îÐÂÑо¿ÎªSIRTµÄ¾«×¼Ó¦ÓÃÌṩÁËÐÂÖ¤¾Ý¡£Ñо¿·¢ÏÖ£¬Ó봫ͳ±ê×¼¼ÁÁ¿Ïà±È£¬¸öÌ廯¼ÁÁ¿·½°¸¿ÉÏÔÖøÌá¸ßHCC»¼ÕßµÄÖÎÁÆÓ¦´ðÂÊ¡£¼²²¡¿ØÖÆ×黼ÕßµÄÖ×ÁöÎüÊÕ¼ÁÁ¿ÏÔÖø¸ßÓÚ¼²²¡½øÕ¹×é¡£´ËÍ⣬ÔÚÈ·±£Ö×ÁöÓ¦´ð¼ÁÁ¿£¨TR£©µÄͬʱ£¬Í¨¹ý¾«È·¿ØÖÆÕý³£¸Î×éÖ¯ÊÜÕÕ¼ÁÁ¿£¬¿ÉÓÐЧ±£»¤½¡¿µ¸ÎʵÖÊÃâÊÜ·ÅÉäÐÔËðÉË[12,18]¡£ÕâЩ·¢ÏÖ´ÙʹȫÇò½éÈëÖÎÁÆÑ§½ç¼ÓÇ¿Á˶ԷÅÉä˨Èû¼ÁÁ¿Ñ§µÄÉîÈëÑо¿£¬ÈÕÒæÈÏʶµ½Á¿»¯ÎüÊÕ¼ÁÁ¿¼°ÆäÓëÖ×ÁöÓ¦´ð¡¢Éú´æ¸ÄÉÆÏà¹ØÐÔ¶Ô¸öÌ廯ÖÎÁƵÄÖØÒªÐÔ¡£½¨Á¢»ùÓÚÌØ¶¨ÈËȺ²ÎÊýµÄ¼ÁÁ¿ãÐÖµ±ê×¼£¬¶Ô¸Ä±äÏÖÓÐÖÎÁÆ·¶Ê½¾ßÓÐÖØ´óÒâÒå¡£ ±¾Ñо¿ÉîÈë̽ÌÖÁËîÆ90΢ÇòÑ¡ÔñÐÔÄÚ·ÅÉäÖÎÁÆ£¨SIRT£©ÔÚ¸Îϸ°û°©£¨HCC£©»¼ÕßÖеļÁÁ¿Ñ§·´Ó¦¡£Í¨¹ý¶Ô²»Í¬»¼ÕßÌØÕ÷ºÍ¸ÎÔ༲²¡³Ì¶ÈµÄ·ÖÎö£¬ÎªÏÖÓÐÖÎÁÆ·½°¸ÌṩÁË»ùÓÚ¼ÁÁ¿µÄ¸öÐÔ»¯ÖÎÁƽ¨Ò飬²¢¶Ô¼²²¡¿ØÖƺÍÖÎÁÆ·´Ó¦×ö³öÁËÔ¤²â¡£Ñо¿»¹Ìرð¹Ø×¢Á˼ÁÁ¿Ñ§²ÎÊýÓë¿Í¹Û»º½âµÄ¹ØÏµ£¬·¢ÏÖÔÚ½ÓÊÜîÆ90΢ÇòµÄ»¼ÕßÖУ¬¸ßÎüÊÕ¼ÁÁ¿Í¨³£Óë¸ü¸ßµÄÖÎÁÆ·´Ó¦ÂÊÏà¹Ø¡£Ñо¿±íÃ÷£¬D30¡¢D50¡¢D70µÈ¼ÁÁ¿Ñ§Ö¸±êÓë¿Í¹Û»º½â³ÊÕýÏà¹Ø£¬Ç¿µ÷ÔÚÖÎÁƼƻ®Öо«×¼¼ÆËã¼ÁÁ¿µÄÖØÒªÐÔ¡£´ËÍ⣬Ö×ÁöµÄÒìÖÊÐÔ¼°Î¢Çò·Ö²¼¶ÔÖÎÁÆÐ§¹û¾ßÓÐÖØÒªÓ°Ï죬Òò´Ë£¬ÔÚÖÆ¶¨ÖÎÁÆ·½°¸Ê±£¬±ØÐ뿼ÂÇÕâЩÒòËØ¡£ Ëæ×ÅîÆ90΢Çò¼¼ÊõµÄÌáÉýºÍÏà¹ØÑо¿µÄ¿ªÕ¹£¬¼ÁÁ¿Ñ§Êý¾Ý²»¶ÏÀ©³ä¡£Í¨¹ý¼ÁÁ¿-·´Ó¦·ÖÎö¿ÉÒÔ·¢ÏÖ£¬¸öÐÔ»¯ÖÎÁÆÔÚ¸Îϸ°û°©ÖÎÁÆÖоßÓÐÖØÒª×÷Óá£Ñо¿Ç¿µ÷ÁËÊ÷֬΢ÇòSIRTÖÎÁƸÎϸ°û°©Ê±¸öÌ廯¼ÁÁ¿²â¶¨µÄÖØÒªÐÔ¡£Í¨¹ýÁ¿»¯ÎüÊÕ¼ÁÁ¿²¢Ã÷È·ÆäÓëÖ×Áö·´Ó¦µÄ¹ØÏµ£¬¿ÉÖÆ¶¨¾«×¼ÖÎÁƲßÂÔÒÔÌáÉýÁÆÐ§£¬ÉõÖÁ¿ÉÄܽ«¹ÃÏ¢ÖÎÁÆ×ª»¯Îª¸ùÖÎÐÔÖÎÁÆ¡£ÕâЩ·¢ÏÖΪ¼ÁÁ¿µ÷ÕûÌṩÁËÖØÒªÒÀ¾Ý£¬²¢Í¹ÏÔÁ˸ÃÁìÓò½øÒ»²½Ñо¿µÄ±ØÒªÐÔ¡£ δÀ´µÄÑо¿¿ÉÒÔ½áºÏеÄÉúÎï±êÖ¾ÎÈç·Ö×ÓÆ×ºÍ×éÖ¯²¡Àíѧ·Ö¼¶£¬½øÒ»²½Ï¸»¯¸öÐÔ»¯ÖÎÁÆ·½°¸£¬²¢ÎªÃ¿Î»»¼ÕßÉ趨²»Í¬µÄ¼ÁÁ¿Ñ§ãÐÖµ¡£ÕâЩŬÁ¦½«Îª¸öÌ廯ÖÎÁÆÌṩÀíÂÛÒÀ¾Ý£¬²¢ÓÐÖúÓÚÍÆ¶¯¸ÃÁìÓòµÄ½øÒ»²½·¢Õ¹¡£ ¸Î°©ÍíÆÚÔõô°ì£¿ÔÚÃæ¶Ô¸Î°©ÍíÆÚ£¬»¼ÕßÓë¼ÒÊôÒ»¶¨²»ÒªÇáÒ×·ÅÆú£¬ÏÖÔÚҽѧÔÚ²»¶Ï½ø²½£¬¸üеÄÖÎÁÆÊֶΣ¬ÏñÒ׸ÊÌ©®îÆ90΢Çò×¢ÉäÒºÒѾÔÚÁÙ´²ÉÏÈ¡µÃÁËÒ»¶¨µÄ³É¼¨£¬Òò´Ë¶àһ˿ϣÍû£¬±£³ÖÁ¼ºÃµÄÐÄÌ¬Ãæ¶Ô¸Î°©¡£ ²Î¿¼ÎÄÏ×£º 1.Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209–249. doi: 10.3322/caac.21660. 2.Abuqbeitah M, Akdag ÖT, Demir M, Asa S, Sönmezoglu K. Simplification of dosimetry in 90 Y-radioembolization therapy by dual planar images. 1288BMC Cancer. 2022;22(1) doi: 10.1186/s12885-022-10392-y. 3.Kudo M, Finn RS, Galle PR, Zhu AX, Ducreux M, Cheng AL, et al. IMbrave150: Efficacy and Safety of Atezolizumab plus Bevacizumab versus Sorafenib in Patients with Barcelona Clinic Liver Cancer Stage B Unresectable Hepatocellular Carcinoma: An Exploratory Analysis of the Phase III Study. Liver Cancer. 2022;12(3):238–250. doi: 10.1159/000528272. 4.Affonso BB, Galastri FL, Leal JM, Filho, Nasser F, Falsarella PM, Cavalcante RN, et al. Long-term outcomes of hepatocellular carcinoma that underwent chemoembolization for bridging or downstaging. World J Gastroenterol. 2019;25(37):5687–5701. doi: 10.3748/wjg.v25.i37.5687. 5.Reig M, Forner A, Rimola J, Ferrer-Fàbrega J, Burrel M, Garcia-Criado Á, et al. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. J Hepatol. 2022;76(3):681–693. doi: 10.1016/j.jhep.2021.11.018. 6.Vilgrain V, Pereira H, Assenat E, Guiu B, Ilonca AD, Pageaux GP, Sibert A, Bouattour M, Lebtahi R, Allaham W, Barraud H, Laurent V, Mathias E, Bronowicki JP, Tasu JP, Perdrisot R, Silvain C, Gerolami R, Mundler O, Seitz JF, Vidal V, Aubé C, Oberti F, Couturier O, Brenot-Rossi I, Raoul JL, Sarran A, Costentin C, Itti E, Luciani A, Adam R, Lewin M, Samuel D, Ronot M, Dinut A, Castera L, Chatellier G, SARAH Trial Group Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial. Lancet Oncol. 2017;18(12):1624–1636. doi: 10.1016/S1470-2045(17)30683-6. 7.Chow PKH, Gandhi M, Tan SB, Khin MW, Khasbazar A, Ong J, Choo SP, Cheow PC, Chotipanich C, Lim K, Lesmana LA, Manuaba TW, Yoong BK, Raj A, Law CS, Cua IHY, Lobo RR, Teh CSC, Kim YH, Jong YW, Han HS, Bae SH, Yoon HK, Lee RC, Hung CF, Peng CY, Liang PC, Bartlett A, Kok KYY, Thng CH, Low AS, Goh ASW, Tay KH, Lo RHG, Goh BKP, Ng DCE, Lekurwale G, Liew WM, Gebski V, Mak KSW, Soo KC, Asia-Pacific Hepatocellular Carcinoma Trials Group SIRveNIB: Selective Internal Radiation Therapy Versus Sorafenib in Asia-Pacific Patients With Hepatocellular Carcinoma. J Clin Oncol. 2018;36(19):1913–1921. doi: 10.1200/JCO.2017.76.0892. 8.Gregory J, Tselikas L, Allimant C, de Baere T, Bargellini I, Bell J, et al. Defining textbook outcome for selective internal radiation therapy of hepatocellular carcinoma: an international expert study. Eur J Nucl Med Mol Imaging. 2023;50(3):921–928. doi: 10.1007/s00259-022-06002-5. [ . 9.Kao YH, Hock Tan AE, Burgmans MC, Irani FG, Khoo LS, Gong Lo RH, et al. Image-guided personalized predictive dosimetry by artery-specific SPECT/CT partition modeling for safe and effective 90Y radioembolization. J Nucl Med. 2012;53(4):559–566. doi: 10.2967/jnumed.111.097469. 10.Srinivas SM, Natarajan N, Kuroiwa J, Gallagher S, Nasr E, Shah SN, et al. Determination of radiation absorbed dose to primary liver tumors and normal liver tissue using post radioembolization 90Y PET. 255Front Oncol. 2014;4(SEP) doi: 10.3389/fonc.2014.00255. 11.Allimant C, Kafrouni M, Delicque J, Ilonca D, Cassinotto C, Assenat E, et al. Tumor Targeting and Three-Dimensional Voxel-Based Dosimetry to Predict Tumor Response, Toxicity, and Survival after Yttrium-90 Resin Microsphere Radioembolization in Hepatocellular Carcinoma. J Vasc Interv Radiol. 2018;29(12):1662–70.e4. doi: 10.1016/j.jvir.2018.07.006. 12.Hermann AL, Dieudonné A, Ronot M, Sanchez M, Pereira H, Chatellier G, Garin E, Castera L, Lebtahi R, Vilgrain V, SARAH Trial Group Relationship of Tumor Radiation-absorbed Dose to Survival and Response in Hepatocellular Carcinoma Treated with Transarterial Radioembolization with 90 Y in the SARAH Study. Radiology. 2020;296(3):673–684. doi: 10.1148/radiol.2020191606. 13.Garin E, Guiu B, Edeline J, Rolland Y, Palard X. Trans-arterial Radioembolization Dosimetry in 2022. Cardiovasc Intervent Radiol. 2022;45(11):1608–1621. doi: 10.1007/s00270-022-03215-x. 14.Lam M, Garin E, Maccauro M, Kappadath SC, Sze DY, Turkmen C, et al. A global eva luation of advanced dosimetry in transarterial radioembolization of hepatocellular carcinoma with Yttrium-90: the TARGET study. Eur J Nucl Med Mol Imaging. 2022;49(10):3340–3352. doi: 10.1007/s00259-022-05774-0. 15.Levillain H, Bagni O, Deroose CM, Dieudonné A, Gnesin S, Grosser OS, et al. International recommendations for personalised selective internal radiation therapy of primary and metastatic liver diseases with yttrium-90 resin microspheres. Eur J Nucl Med Mol Imaging. 2021;48(5):1570–1584. doi: 10.1007/s00259-020-05163-5. 16.Veenstra EB, Ruiter SJ, de Haas RJ, Bokkers RP, de Jong KP, Noordzij W. Post-treatment three-dimensional voxel-based dosimetry after Yttrium-90 resin microsphere radioembolization in HCC. 9EJNMMI Res. 2022;12(1) doi: 10.1186/s13550-022-00879-x. 17.Villalobos A, Arndt L, Cheng B, Dabbous H, Loya M, Majdalany B, et al. Yttrium-90 Radiation Segmentectomy of Hepatocellular Carcinoma: A Comparative Study of the Effectiveness, Safety, and Dosimetry of Glass-Based versus Resin-Based Microspheres. J Vasc Interv Radiol. 2023;34(7):1226–1234. doi: 10.1016/j.jvir.2023.02.030. 18.Garin E, Tselikas L, Guiu B, Chalaye J, Edeline J, de Baere T, Assenat E, Tacher V, Robert C, Terroir-Cassou-Mounat M, Mariano-Goulart D, Amaddeo G, Palard X, Hollebecque A, Kafrouni M, Regnault H, Boudjema K, Grimaldi S, Fourcade M, Kobeiter H, Vibert E, Le Sourd S, Piron L, Sommacale D, Laffont S, Campillo-Gimenez B, Rolland Y, DOSISPHERE-01 Study Group Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial. Lancet Gastroenterol Hepatol. 2021;6(1):17–29. doi: 10.1016/S2468-1253(20)30290-9 |